Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application

Fengting Ou; Ying Zhou; Jinxiu Lei; Su Zeng; Fuhai Wu; Ning Zhang; Lushan Yu

doi:10.1016/j.jpha.2019.09.002

Volume 10 Issue 6

Dec. 2020

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2020 > 10(6): 617-623

Fengting Ou, Ying Zhou, Jinxiu Lei, Su Zeng, Fuhai Wu, Ning Zhang, Lushan Yu. Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application[J]. Journal of Pharmaceutical Analysis, 2020, 10(6): 617-623. doi: 10.1016/j.jpha.2019.09.002

Citation:

Fengting Ou, Ying Zhou, Jinxiu Lei, Su Zeng, Fuhai Wu, Ning Zhang, Lushan Yu. Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application[J]. Journal of Pharmaceutical Analysis, 2020, 10(6): 617-623. doi: 10.1016/j.jpha.2019.09.002

Citation:

Fengting Ou, Ying Zhou, Jinxiu Lei, Su Zeng, Fuhai Wu, Ning Zhang, Lushan Yu. Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application[J]. Journal of Pharmaceutical Analysis, 2020, 10(6): 617-623. doi: 10.1016/j.jpha.2019.09.002

PDF( 710 KB)

Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application

doi: 10.1016/j.jpha.2019.09.002

Fengting Ou^a,b,
Ying Zhou^a,
Jinxiu Lei^a,
Su Zeng^a,
Fuhai Wu^c,
Ning Zhang^{d
,
,},
Lushan Yu^{a
,
,}

a. Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China;
b. School of Pharmacy, Guangdong Pharmaceutical University, Guangdong, 510006, China;
c. School of Public Health, Guangdong Pharmaceutical University, Guangdong, 510006, China;
d. Institute of Nuclear Agricultural Sciences, Zhejiang University, Hangzhou, 310058, China

Funds:

D Program of China (No. 2017YFE0102200), and the Fundamental Research Funds for the Central Universities (2017XZZX011-04).

This work was supported by grants from the National Key Research and Development Program of China (2017YFC0908600), the National Natural Science Foundation of China (81773817), the National Key R&

Received Date: Jun. 17, 2019
Accepted Date: Sep. 17, 2019
Rev Recd Date: Sep. 12, 2019
Available Online: Jan. 24, 2022
Publish Date: Dec. 10, 2020

Abstract

Abstract

In Korea and China, ilaprazole is a widely used proton pump inhibitor in the treatment of gastric ulcers. In this study, a specific and sensitive LC-MS/MS method has been developed and validated for the quantification of ilaprazole enantiomers in the rat plasma, using R-lansoprazole as the internal standard. The enantioseparation was achieved on a CHIRALPAK AS-RH column (4.6 mm × 150 mm, i.d. 5 μm), with a mobile phase composed of 10 mM ammonium acetate aqueous solution and acetonitrile (60:40, V/V), at a flow-rate of 0.5 mL/min. The method was validated over the concentration range of 0.5–300 ng/mL for both, R- and S -ilaprazole. The lower limit of quantification was 0.5 ng/mL for both enantiomers. The relative standard deviation (RSD) of intra- and inter-day precision of R-ilaprazole and S-ilaprazole was less than 10.9%, and the relative error accuracy (RE) ranged from −0.5%–2.0%. Finally, the method was successfully evaluated in rats in a stereoselective pharmacokinetic study of the ilaprazole racemate.
- Ilaprazole,
- Enantiomer,
- LC-MS/MS,
- Pharmacokinetics

FullText(HTML)

References(22)

References

V.D. Corleto, S. Festa, E. Di Giulio, et al., Proton pump inhibitor therapy and potential long-term harm, Curr. Opin. Endocrinol. Diabetes Obes. 21 (2014) 3-8

E. Savarino, A. Ottonello, I. Martinucci, et al., Ilaprazole for the treatment of gastro-esophageal reflux, Expert. Opin. Pharmacother. 17 (2016) 2107-2113

N.P. Bohidar, K. Krishna, B.K. Panda, et al., Ilaprazole: Is this a superior proton pump inhibitor for duodenal ulcer? Trop. Gastroenterol. 34 (2013) 95-98

J.W. Xuan, R.L. Song, G.X. Xu, et al., Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China, J. Med. Econ. 19 (2016) 1056-1060

X.Q. Ji, J.F. Du, G. Chen, et al., Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis, World J. Gastroenterol. 20 (2014) 5119-5123

L. Wang, L. Zhou, S. Lin, et al., ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial, J. Clin. Gastroenterol. 45 (2011) 322-329

K.A. Seo, S.J. Lee, K.B. Kim, et al., Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5, Xenobiotica. 42 (2012) 278-284

G. Zhou, Z.R. Tan, W. Zhang, et al., An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study, Acta Pharmacol. Sin. 30 (2009) 1330-1336

H. Wang, N. Ou, L. Lang, et al., Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses, Xenobiotica 46 (2012) 1133-1141

H. Cho, M.K. Choi, D.Y. Cho, et al., Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics and pharmacodynamics of a new proton pump inhibitor, ilaprazole, J. Clin. Pharmacol. 52 (2013) 976-984

H.Y W, L.W L, N. Ou, et al. Pharmacokinetics, pharmacodynamics and safety of multiple-infusion ilaprazole in healthy Chinese subjects. Clin. Drug Investig. 36 (2016) 463-470

Z.W. Shen, C. Lv, S. Zeng, Significance and challenges of stereoselectivity assessing methods in drug metabolism, J. Pharm. Anal. 6 (2016) 1-10

Z.Z. Yang, L. Li, L. Wang, et al., The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants, Acta Pharmacol. Sin. 38 (2017) 1184-1194

L.S. Yu, J.B. Pu, M.J. Zuo, et al., Hepatic Glucuronidation of isoneochamaejasmin A from the traditional Chinese medicine stellera chamaejasme L. root, Drug Metab. Dispos. 42 (2014) 735−743

Q. Shen, L. Wang, H. Zhou, et al., Stereoselective binding of chiral drugs to plasma proteins, Acta Pharmacol. Sin. 34 (2013) 998−1006

R. Fass, R. Frazier, The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease, Therap. Adv. Gastroenterol. 10 (2017) 243-251

L.N. Chennuru, T. Choppari, S. Duvvuri, et al., Enantiomeric separation of proton pump inhibitors on new generation chiral columns using LC and supercritical fluid chromatography, J. Sep. Sci. 36(2013) 3004-3010

Z.R Tan, Y.C Wang, Y. Chen, et al. Development and validation of a LC-MS/MS method for the determination of ilaprazole enantiomers and its application to a bioequivalence study in healthy Chinese volunteers, Chromatographia 75 (2012) 95-101

M. Miura, Enantioselective disposition of lansoprazole and rabeprazole in human plasma, Yakugaku Zasshi 126 (2006) 395-402

K.A. Kim, J.H. Shon, J.Y. Park, et al., Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19, Clin. Pharmacol. Ther. 72 (2002) 90-99

M. Tanaka, Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin, Clin. Pharmacol. Ther. 69 (2001) 108-113

A. Abelo, T.B. Andersson, M. Antonsson, et al., Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes, Drug Metab. Dispos. 28 (2000) 966-972

Relative Articles

Supplements(0)

Cited By

Proportional views